The in vitro diagnostics market continues its push to bring molecular testing closer to patients. The latest example is bioMérieux's submission of a dual 510(k)/CLIA waiver application to the US Food and Drug Administration for its BIOFIRE SPOTFIRE Vaginitis Panel.
If cleared, the multiplex PCR assay would bring another molecular test directly into an exam room by enabling physicians to diagnose vaginitis in approximately 20 minutes during a single patient visit. This is in line with other rapid molecular tests for COVID-19, influenza, and certain sexually transmitted infections.
For clinical laboratory professionals, the submission signals two industry trends:
- Continued investment in syndromic molecular testing
- Growing competition among IVD manufacturers to expand molecular diagnostics into near-patient and point-of-care settings
The BIOFIRE SPOTFIRE Vaginitis Panel is designed to detect bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, and other common pathogens from a single vaginal swab. According to bioMérieux, the test reports eight results from one specimen during a routine office visit.
Women's health draws IVD investment
Women's health has become an increasingly attractive market for diagnostic manufacturers as molecular testing replaces traditional methods that can be less sensitive and more subjective. Vaginitis is one of the most common reasons women seek gynecologic care, yet conventional testing often leads to inappropriate treatment when the underlying cause is not accurately identified.
bioMérieux said the submission represents its first move into women's and sexual health testing, expanding the BIOFIRE SPOTFIRE platform beyond respiratory and sore throat panels.
"Today, there is a clear and persistent gap in vaginitis diagnostics," Jennifer Zinn, executive vice president of clinical operations at bioMérieux, said in a statement. "With the BIOFIRE SPOTFIRE Vaginitis Panel, bioMérieux is addressing this gap by bringing fast, syndromic molecular testing directly to the point of care."
Clinicians frequently rely on subjective exams or microscopic evaluations that carry high rates of misdiagnosis, while more accurate laboratory PCR tests can take days to return results. A 2021 clinical study published in Obstetrics & Gynecology compared standard clinician diagnoses against automated molecular PCR testing. It found that standard clinical exams missed 45.3% of positive cases and misidentified 12.3% of negative cases as positive. Rapid point-of-care PCR testing can help close that gap.
The company added that only about half of women diagnosed with vaginitis using non-molecular testing receive appropriate treatment, citing research published in May in the journal Sexually Transmitted Diseases that focused on a test by Cepheid, a competing IVD manufacturer.
Laboratory market implications
Although intended for point-of-care use, the bioMérieux assay reflects broader changes in the diagnostics market. CLIA-waived molecular testing continues to expand beyond respiratory diseases into additional specialties, creating new opportunities for physician office testing while increasing the need for laboratory oversight and quality management.
The FDA submission also shows how major IVD manufacturers are broadening syndromic testing menus beyond respiratory diagnostics. As companies compete to build comprehensive molecular portfolios, women's health is emerging as another important growth segment for the diagnostics industry.
The growing emphasis on expanding women's health diagnostics extends beyond vaginitis testing. According to an article from Dark Daily’s sibling publication, Today’s Clinical Lab, a large real-world study from Kaiser Permanente Washington found that offering mailed and in-clinic HPV self-collection kits increased cervical cancer screening rates, reduced clinician-performed pelvic exams by more than one-third, and improved follow-up care for patients with positive HPV results. The findings suggest self-collection programs could expand screening access while creating new opportunities for laboratories to support molecular HPV testing and coordinated patient management.
